Telomerase and cancer: Time to move from a promising target to a clinical reality

Journal of Pathology

Volumn 195, Issue 4, 2001, Pages 404-414

  Nicol Keith, W ^a   Jeffry Evans, T R ^a   Glasspool, Rosalind M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Anti cancer treatment; Cellular senescence; Inhibitors; Oncogenesis; Telomerase

Indexed keywords

CYTOTOXIC AGENT; MONOCLONAL ANTIBODY; TELOMERASE; TELOMERASE INHIBITOR;

APOPTOSIS; CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELL IMMORTALIZATION; CELL INVASION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN CELL; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SENESCENCE;

ANIMALS; CELL AGING; CELL DEATH; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; NEOPLASMS; PATIENT SELECTION; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0035171612     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1001     Document Type: Review

References (158)

1. Hayflick, his limit, and cellular ageing
2. A reassessment of the telomere hypothesis of senescence
3. The role of senescence and immortalization in carcinogenesis
4. Role of telomerase in normal and cancer cells
5. Role of telomerase in cellular proliferation and cancer
6. Telomerase and cancer
7. Stable association of hsp90 and p23, but not hsp70, with active human telomerase
8. Functional requirement of p23 and Hsp90 in telomerase complexes
9. Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells
10. Functional evidence for a telomerase repressor gene on human chromosome 10p15.1
11. Telomerase suppression by chromosome 6 in a human papillomavirus type 16-immortalized keratinocyte cell line and in a cervical cancer cell line
12. In situ hybridization analysis of the expression of human telomerase RNA in normal and pathologic conditions of the skin
13. Telomerase activity concentrates in the mitotically active segments of human hair follicles
14. Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes
15. Cutting edge: Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation
16. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes
17. Alternative splicing of the telomerase catalytic subunit in human oocytes and embryos
18. Telomerase activity in germ cell cancers and mature teratomas
19. Expression of the RNA component of telomerase during human development and differentiation
20. Telomerase activity in human germline and embryonic tissues and cells
21. Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization
22. Regulation of telomerase activity in normal and malignant human cells
23. Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells
24. Telomerase expression prevents replicative senescence but does not fully reset mRNA expression patterns in Werner syndrome cell strains
25. Telomerase activity does not always imply telomere maintenance
26. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase
27. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase
28. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span
29. Extension of life-span by introduction of telomerase into normal human cells
30. Telomeres, telomerase, and cancer: Life on the edge of genomic stability
31. A telomerase component is defective in the human disease dyskeratosis congenita
32. Telomerase: A promising marker of biological immortality of germ, stem, and cancer cells. A review
33. A survey of telomerase activity in human cancer
34. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death
35. Inhibition of telomerase limits the growth of human cancer cells
36. Telomere maintenance by recombination in human cells
37. Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomere cells is associated with methylation of the hTERC promoter
38. Alternative lengthening of telomeres in human cells
39. Essential role of mouse telomerase in highly proliferative organs
40. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis
41. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse
42. Telomerase activation, cellular immortalization and cancer
43. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis
44. Functional-characterization and developmental regulation of mouse telomerase RNA
45. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA
46. Telomerase inhibition in RenCa, a murine tumor cell line with short telomeres, by overexpression of a dominant negative mTERT mutant, reveals fundamental differences in telomerase regulation between human and murine cells
47. Telomerase activation in mouse mammary tumors: Lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation
48. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation
49. Impaired germinal center reaction in mice with short telomeres
50. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors
51. Telomerase as an anti-cancer drug target: Will it fulfil its early promise?
52. Severe growth defect in mouse cells lacking the telomerase RNA component
53. Developmental and tissue-specific regulation of mouse telomerase and telomere length
54. Longevity, stress response, and cancer in aging telomerase-deficient mice
55. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology
56. Cloning and characterization of human and mouse telomerase RNA gene promoter sequences
57. Activation of telomerase RNA gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3
58. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma
59. Change in telomerase activity during human colorectal carcinogenesis
60. Detection of telomerase activity in biopsy samples of colorectal cancer
61. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues
62. Telomerase in (pre)neoplastic cervical disease
63. Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors
64. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors
65. Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis
66. Demonstration of constant upregulation of the telomerase RNA component in human gastric carcinomas using in situ hybridization
67. Is small cell lung cancer the perfect target for anti-telomerase treatment?
68. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine
69. Comparison of screening methods in detection of bladder cancer
70. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity
71. Telomerase activity - Simplification of assay and detection in bladder tumor and urinary exfoliated cells
72. Diagnosis of bladder cancer using telomerase activity in voided urine
73. Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma
74. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer
75. Expression of the RNA component of human telemorase (hTR) in ThinPrep preparations from bladder washings
76. Detection of telomerase reverse transcriptase mRNA in biopsy specimens and bile for diagnosis of biliary tract cancers
77. Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms
78. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms
79. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms
80. In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies
81. Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms
82. Detection of telomerase activity in exfoliated cancer cells obtained from bile
83. Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers
84. PCR and in situ hybridization studies of telomerase subunits in human non-neoplastic livers
85. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy
86. Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear
87. Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer
88. Predicting the future: A critical appraisal of cancer prognosis studies
89. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor
90. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma
91. Telomerase activity and survival of patients with node-positive breast cancer
92. Prognostic value of proliferation index and expression of the RNA component of human telomerase (hTR) in papillary meningiomas
93. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness
94. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer
95. Quantification of telomerase activity in sporadic colorectal carcinoma: Association with tumor growth and venous invasion
96. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay
97. Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas
98. Telomerase activity is a useful marker to distinguish malignant pancreatic cystic tumors from benign neoplasms and pseudocysts
99. Prognostic significance of telomerase activity in soft tissue sarcomas
100. Quantitation of telomerase activity in hepatocellular carcinoma: A possible aid for a prediction of recurrent diseases in the remnant liver
101. Telomerase activity significantly correlates with cell differentiation, proliferation and lymph node metastasis in colorectal carcinomas
102. Telomerase activity as a prognostic factor in neuroblastomas
103. Telomerase activity and telomerase subunit gene expression patterns in neuroblastoma: A molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues
104. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis
105. Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas
106. Prognostic impact of telomerase activity in patients with neuroblastoma
107. Correlating telomerase activity levels with human neuroblastoma outcomes
108. Telomerase activity in neuroblastoma: Is it a prognostic indicator of clinical behaviour?
109. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay
110. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase
111. FJ5002: A potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis
112. Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates
113. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells
114. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides
115. Cellular delivery of peptide nucleic acids and inhibition of human telomerase
116. Inhibition of human telomerase by PNA-cationic peptide conjugates
117. G-quadruplexes as targets for drug design
118. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells
119. Adenoviral expression of p53 represses telomerase activity through down- regulation of human telomerase reverse transcriptase transcription
120. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells
121. Inhibition of human telomerase by a retrovirus expressing telomeric antisense RNA
122. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity
123. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis
124. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture
125. Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells
126. Telomerase inhibition by induced expression of antisense RNA
127. Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines
128. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins
129. Inhibition of human telomerase activity by peptide nucleic acids
130. Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones
131. Inhibition of human telomerase by 2′-O-methyl-RNA
132. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells
133. Inhibition of human telomerase by a G-quadruplex-interactive compound
134. Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection reagent, FuGENE6, in HeLa cells
135. Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid construct in human melanoma cells
136. Inhibition of human telomerase by 7-deaza-2′-deoxyguanosine nucleoside triphosphate analogs: Potent inhibition by 6-thio-7-deaza-2′-deoxyguanosine 5′-triphosphate
137. Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay
138. Synthetic 2′-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity
139. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas
140. The development of telomerase inhibitors: The G-quartet approach
141. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA
142. Antisense telomerase treatment: Induction of two distinct pathways, apoptosis and differentiation
143. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers
144. A novel telomerase-specific gene therapy: Gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter
145. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters
146. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs
147. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents
148. Mammalian Ku86 protein prevents telomeric fusions independently of the length of TTAGGG repeats and the G-strand overhang
149. Telomerase subunit overexpression suppresses telomere-specific checkpoint activation in the yeast yku80 mutant
150. Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability
151. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2)
152. Clinical trials of Herceptin (trastuzumab)
153. Breast cancer in the 21st century: Neu opportunities and neu challenges
154. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials
155. Telomerase activity in pleural effusions: Diagnostic significance
156. Telomerase activity in lung cancer cells obtained from bronchial washings
157. Telomerase expression in cerebro-spinal fluid specimens as an adjunct to cytologic diagnosis
158. Telomerase activity in the female reproductive tract and neoplasms